Allopurinol can and frequently does trigger gout attacks, especially during the first several months of treatment. Roughly four out of ten people who start allopurinol on a treat-to-target regimen experience at least one flare in the early phase of therapy. This paradox, where a drug meant to prevent gout actually provokes it, is one of the most frustrating aspects of gout management and a major reason people stop taking the medication before it has a chance to work.
Why a Drug That Lowers Uric Acid Would Trigger a Flare
Gout flares happen when the immune system reacts to monosodium urate (MSU) crystals deposited in joints and surrounding tissues. These crystals trigger a cascade of inflammatory signaling, producing intense pain, swelling, and redness.1Europe PMC. The Mechanism of the NLRP3 Inflammasome Activation and Pathogenic Implication in the Pathogenesis of Gout Allopurinol works by reducing the amount of uric acid your body produces, which over time brings uric acid levels below the threshold at which crystals form. Existing crystals gradually dissolve, and new ones stop accumulating. The problem is what happens during that dissolution process.
When uric acid levels shift, whether up or down, the crystal deposits in your joints undergo remodeling. Crystals that were stable and partially coated by proteins get exposed to the surrounding tissue as they shrink and break apart. This newly exposed crystal surface is what the immune system reacts to. In other words, the very process of clearing out the crystals that cause gout also temporarily makes those crystals more visible to the inflammatory machinery. A paradoxical increase in flare risk following initiation of urate-lowering therapy is a well-recognized clinical challenge.2Nature Reviews Rheumatology. When underlying biology threatens the randomization principle – initial gout flares of urate-lowering therapy
Think of it like disturbing sediment at the bottom of a lake. The sediment was already there, but stirring it up temporarily makes the water murkier. The flares people experience on allopurinol are not caused by new crystal formation; they are caused by the disruption of crystals that were already present. This is why the flares are temporary: once enough crystals have dissolved, there is less material left to provoke inflammation.
How Common Are These Flares, and How Long Do They Last?
In a post-hoc analysis of a randomized multicenter trial, at least one flare was observed in about 42% of participants assigned to allopurinol during the initial treatment phase.3PubMed Central. A Comparison of Gout Flares with the Initiation of Treat-to-Target Allopurinol and Febuxostat: A Post-hoc Analysis of a Randomized Multicenter Trial That is not a trivial number. For someone who starts allopurinol hoping to get fewer gout attacks, having a coin-flip chance of getting one (or several) in the early months feels like the treatment is making things worse.
The flares tend to cluster in the first three to six months of therapy and then taper off as the uric acid level stabilizes and the crystal burden decreases. This timeline varies from person to person. People who enter treatment with a heavier crystal load, including those with visible tophi or gout that affects multiple joints, tend to experience more flares and for a longer period. Someone with a single joint occasionally affected may have a milder experience during the transition.
Over the long term, the picture reverses. Maintaining uric acid below the saturation threshold with urate-lowering therapy leads to dissolution of MSU crystals and, eventually, suppression of gout flares and regression of tophi.4The Journal of Rheumatology. What Is Allopurinol Failure and What Should We Do About It? The early flares are the turbulence before the calm, but the calm does come for most people who stick with treatment.
Why “Start Low, Go Slow” Matters
One of the strongest predictors of early flares is how quickly allopurinol is introduced. Older prescribing habits sometimes involved starting at a full dose of 300 mg daily. Current guidelines overwhelmingly recommend starting at a low dose, often 100 mg daily or even lower, and increasing gradually every few weeks until the target uric acid level is reached. This approach, often called “start low, go slow,” minimizes the rate of uric acid change and gives the crystal deposits time to adjust more gradually.
The logic is straightforward: a slower drop in uric acid means a slower rate of crystal remodeling, which means fewer inflammatory triggers at any given moment. It does not eliminate flares entirely, but it reduces their frequency and severity compared to jumping straight to a high dose. For people with kidney impairment, starting even lower is standard practice, since the drug clears more slowly and the kidneys are already under strain.
Preventing Flares While Starting Allopurinol
Because early flares are so common, most rheumatology guidelines recommend taking a preventive anti-inflammatory medication alongside allopurinol for the first several months. The two main options are low-dose colchicine and low-dose NSAIDs like naproxen.5PubMed. Prophylaxis for acute gout flares after initiation of urate-lowering therapy International rheumatology society guidelines specifically recommend colchicine prophylaxis when starting urate-lowering therapy.6PubMed. Cost-Effectiveness of Colchicine Prophylaxis for Gout Flares When Commencing Allopurinol
Colchicine at a low dose (typically 0.5 mg once or twice a day) given for up to six months during allopurinol initiation reduces both the frequency and severity of flares and lowers the chance of recurrent attacks.7PubMed. Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis A randomized trial confirmed that six months of low-dose colchicine during start-low-go-slow allopurinol initiation suppressed gout flares, and that placebo did not meet the non-inferiority threshold when compared with colchicine.8Annals of the Rheumatic Diseases. Is colchicine prophylaxis required with start-low go-slow allopurinol dose escalation in gout? A non-inferiority randomised double-blind placebo-controlled trial In practical terms, that means even when using the gradual dosing approach, adding colchicine still provides measurable benefit over going without it.
For people who cannot take colchicine, perhaps because of kidney problems, drug interactions, or gastrointestinal side effects, a low-dose NSAID is the standard alternative. A retrospective study found that etoricoxib (a selective anti-inflammatory) performed comparably to colchicine in preventing flares during the first 16 weeks of therapy, with somewhat fewer flare days per patient.9Europe PMC. Prophylaxis on gout flares after the initiation of urate-lowering therapy: a retrospective research Patients who received no prophylaxis at all had the highest flare rates.
Can You Start Allopurinol During an Active Flare?
This is one of the most debated practical questions in gout management. For decades, the standard advice was to wait until a gout attack had completely resolved before starting allopurinol, based on the fear that changing uric acid levels mid-flare would make the attack worse. Two randomized trials have challenged that assumption.
One trial compared starting allopurinol during an acute gout flare versus waiting, and found the median time to complete resolution was about six days in both groups, with no significant difference.10PubMed. Early versus Late Allopurinol Initiation in Acute Gout Flare (ELAG): a randomized controlled trial A separate trial reported similar results: 15.4 days to resolution in the allopurinol group versus 13.4 days in the placebo group, a difference that was not statistically meaningful.11PubMed. Does starting allopurinol prolong acute treated gout? A randomized clinical trial Neither trial found an increase in serious adverse events from early initiation.
These findings suggest that starting allopurinol during a flare does not make the flare worse or significantly prolong it. This is useful because gout flares are often the event that finally brings someone to the doctor. If the old rule was to wait, patients would leave the office without the medication they needed, and a meaningful number would never follow up to start it later. Starting allopurinol at the same visit, along with appropriate anti-inflammatory treatment for the active flare, removes that gap.
When Early Flares Cause People to Quit
The early flares are not just uncomfortable; they are a leading reason people abandon allopurinol before it has time to work. Research on patient perspectives found that gout flares were a significant barrier to adherence, and that patients frequently discontinued therapy when allopurinol was perceived as ineffective or even harmful. Discontinuation often coincided with patients experiencing flares while faithfully taking the medication and receiving suboptimal advice about why those flares were happening.12PubMed. Optimizing adherence to allopurinol for gout: patients’ perspectives
This is one of the most important practical takeaways. If you start allopurinol and get a flare in the first couple of months, the natural instinct is to blame the new medication and stop taking it. From the patient’s perspective, the logic is hard to argue with: “I started this pill and got worse, so the pill must be the problem.” But stopping and restarting later resets the clock and subjects you to the same early flare risk again. The drug needs several months of consistent use at the right dose to clear the crystal burden enough that flares become infrequent.
Clear communication from prescribers makes a real difference here. People who are warned in advance that early flares are expected, temporary, and actually a sign that the drug is working tend to push through. People who are not warned tend to quit. If you are starting allopurinol and your doctor has not mentioned that early flares are possible, ask about it directly and about whether a prophylactic medication like colchicine is appropriate for you.
Does Allopurinol Cause More Flares Than Other Urate-Lowering Drugs?
Febuxostat is the other commonly prescribed drug that works by blocking uric acid production. A natural question is whether switching to febuxostat would avoid the early flare problem. The answer, based on the available evidence, is no. In a post-hoc analysis of a large trial, about 42% of people on allopurinol and 46% of people on febuxostat experienced at least one flare during the initial treatment phase, with no statistically significant difference between the two drugs.3PubMed Central. A Comparison of Gout Flares with the Initiation of Treat-to-Target Allopurinol and Febuxostat: A Post-hoc Analysis of a Randomized Multicenter Trial The hazard ratio for flare risk between the two was essentially one, even after adjusting for other factors.
This makes biological sense. The early flares are not a peculiarity of allopurinol’s chemistry; they are a consequence of lowering uric acid and disturbing crystal deposits, regardless of which drug does the lowering. Any effective urate-lowering therapy carries the same risk during the transition period. The same prophylaxis strategies apply whether you are taking allopurinol, febuxostat, or a uricosuric agent.
A Serious but Rare Side Effect Worth Knowing About
While flares are the most common unwanted effect of allopurinol, there is a separate and much rarer concern that deserves mention: a severe skin reaction. People who carry a specific genetic marker called HLA-B*58:01 have a substantially higher risk of developing serious cutaneous adverse reactions to allopurinol. This risk is dramatically amplified by kidney impairment. In one study, the odds ratio climbed from about 15 for someone with the gene and normal kidney function to over 1,200 for someone who was homozygous for the gene and had severe kidney impairment.13PubMed. Impact of the HLA-B(*)58:01 Allele and Renal Impairment on Allopurinol-Induced Cutaneous Adverse Reactions
This genetic marker is more common in certain populations, particularly people of Southeast Asian, Korean, and African American descent. Guidelines increasingly recommend genetic testing before starting allopurinol in these groups. If you carry HLA-B*58:01, allopurinol is generally avoided entirely in favor of an alternative like febuxostat. This is a completely different issue from the gout flare question: flares are a temporary nuisance related to how the drug works, while this skin reaction is a true adverse drug reaction related to immune hypersensitivity.
How Long Before the Flares Actually Stop
There is no single clean cutoff. Most people see a meaningful reduction in flares within six to twelve months of reaching their target uric acid level, which itself can take several months to achieve during dose titration. People with large crystal burdens, especially those with tophi, may continue to have occasional flares for a year or more as the deposits slowly dissolve.
The critical variable is not just taking allopurinol but taking enough of it to bring uric acid below the saturation point, typically below 6 mg/dL, and for many rheumatologists, below 5 mg/dL. A Cochrane review of allopurinol trials found that at a standard dose of 300 mg daily, acute gout attacks were not significantly reduced compared to placebo, though the evidence came from a small trial.14Cochrane Database of Systematic Reviews. Allopurinol for chronic gout This underscores that allopurinol only prevents flares if the dose is high enough to bring uric acid to target, something that does not happen automatically at a fixed 300 mg dose for everyone. Many people need more, and some need less. Regular uric acid monitoring during dose adjustment is what separates successful treatment from frustrated patients who think the drug does not work.
The picture that emerges from the research is nuanced but ultimately encouraging. Allopurinol does cause gout flares in the short term, and that early worsening is not a failure of treatment but a predictable consequence of crystal dissolution. Managing through it with prophylaxis, gradual dosing, and realistic expectations gives the drug the time it needs to do what it was prescribed for: clearing the uric acid load that drives gout in the first place.